Tenofovir alafenamide: An effective option for HIV treatment with reduced risk

Darren Wong, Robert Grossberg

Research output: Contribution to journalArticlepeer-review


Tenofovir disoproxil fumarate has rapidly become an integral part of HIV antiretroviral regimens throughout the world. The advancement of increasingly effective therapeutics has led to a new frontier in HIV treatment, notably the search for options that retain high potency but improved tolerability and long-term safety profiles. Tenofovir alafenamide is a new investigational prodrug developed by Gilead Sciences, Inc. Tenofovir alafenamide has enhanced tissue distribution, specifically into lymphoid tissue, providing increased delivery of active drug to the target site of viral replication. This property may enhance drug activity and allow for a lower required oral administered dose, lower plasma drug levels and reduced adverse effects on the kidney and bone.

Original languageEnglish (US)
Pages (from-to)1069-1075
Number of pages7
JournalFuture Virology
Issue number9
StatePublished - Sep 1 2015


  • HBV
  • HIV
  • antiretroviral
  • tenofovir

ASJC Scopus subject areas

  • Virology


Dive into the research topics of 'Tenofovir alafenamide: An effective option for HIV treatment with reduced risk'. Together they form a unique fingerprint.

Cite this